Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259309 · ClinicalTrials.gov registry record · Early Phase 1
Immune Modulation by Misoprostol
A Early Phase 1 study of Gynecological Infection, sponsored by Vanderbilt University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02259309: Completed Early Phase 1 study of Gynecological Infection, sponsored by Vanderbilt University.
NCT02259309 is a Early Phase 1 study of Gynecological Infection that has completed, run by Vanderbilt University. The registered enrollment target is 15 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02259309, a Early Phase 1 study of Gynecological Infection, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.
Primary Outcome
Peripheral blood collected at Days 0, 1, 28, and 29
Conditions Studied
Interventions
- DRUG Misoprostol - buccal
- DRUG Misoprostol - vaginal
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-11 |
| Phase | Early Phase 1 |
What the finished NCT02259309 record still lists
NCT02259309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Gynecological Infection appearing as the primary indexed condition, and to 2 interventions - of which Misoprostol - buccal is the first listed.
NCT02259309 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02259309 about?
NCT02259309 is a clinical study titled "Immune Modulation by Misoprostol". The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.
What is the current status of trial NCT02259309?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2014-11. Estimated completion is 2015-11.
What conditions does trial NCT02259309 study?
This clinical trial studies the following conditions: Gynecological Infection.
What interventions are being tested in trial NCT02259309?
The interventions under investigation include: Misoprostol - buccal (DRUG), Misoprostol - vaginal (DRUG).
Who is sponsoring clinical trial NCT02259309?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02259309 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02259309's enrollment target sits among peer trials
15 1404th of 2000 higher than 527 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia